CareLit Fachartikel
Canagliflozin, a Sodium Glucose co-transporter 2 (SGLT2) inhibitor, improves indices of β-cell function in patients with type 2 diabetes on metformin plus sulphonylurea
D Polidori, F Vercruysse, E Ferrannini · Diabetologie und Stoffwechsel · 2013 · Heft 04
Dokument
1081169
CareLit-ID
Jahr
2013
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig
Bibliografische Angaben
Zusammenfassung
Question: Progressive loss of β-cell function (βCF) is thought to underlie the pathophysiology of type 2 diabetes mellitus (T2DM). Canagliflozin (CANA), an inhibitor of SGLT2, is in development for the treatment of T2DM. In hyperglycaemic, partially pancreatectomised rats, βCF can be restored when normoglycaemia is achieved with SGLT2 inhibitor treatment. In a Phase 3 study, 26 weeks of CANA monotherapy treatment improved glycaemic control and indices of βCF in patients with T2DM inadequately controlled with diet and exercise. To further assess the effects of CANA on βCF, indices of βCF were evaluated in a Phase…
Schlagworte
Canagliflozin
Diabetes Mellitus
C-Peptide
Diet
After
Diabetologie und Stoffwechsel
